Yet another Low-Dose Aspirin study.

[pjoshea13]

New study from Hong Kong [1].

"... adults with aspirin prescription for at least six months between 2000 and 2004 were included and followed up until 2013."

"A total of 204,170 aspirin users and 408,339 non-aspirin users were included, with the mean age 67.5 years, 7.7 years average duration of aspirin prescription, and 80mg as the median dose of aspirin."

"... aspirin usage led to significant reduction of cancers in liver (RR:0.49); stomach (RR:0.42); colorectum (RR:0.71); lung (RR:0.65); pancreas (RR:0.54); oesophagus (RR:0.59); and leukaemia (RR:0.67)."

"There was no demonstrable reduction of kidney cancer, bladder cancer, prostate cancer and multiple myeloma in association with the usage of aspirin."

"Risk of breast cancer was shown to marginally increase (RR:1.14) with aspirin usage."

***

Note that: "Prostate cancer is the fifth leading cause of male cancer deaths in Hong Kong."

-Patrick

[1] ncbi.nlm.nih.gov/pubmed/305...

Int J Cancer. 2018 Dec 21. doi: 10.1002/ijc.32083. [Epub ahead of print]

Long-Term Use of Low-Dose Aspirin for Cancer Prevention: A 10-year Population Cohort Study in Hong Kong.

Tsoi KK1,2, Ho JM2, Chan FC1, Sung JJ1,3.

Author information

1

Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of Hong Kong.

2

Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong.

3

Department of Medicine and Therapeutics, The Chinese University of Hong Kong.

Abstract

Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, has been found to possess protective effects against cancer development in the Western populations. Such effects amongst Asian populations remain uncertain. The objective of this study is to investigate the use of aspirin on prevention of different cancers among Chinese users. This population-based study utilized database from the Hong Kong Hospital Authority; adults with aspirin prescription for at least six months between 2000 and 2004 were included and followed up until 2013. Aspirin users were age-sex matched with non-aspirin users at a 1:2 ratio. Incidences of cancer were the primary outcome measured by relative risk (RR). A total of 204,170 aspirin users and 408,339 non-aspirin users were included, with the mean age 67.5 years, 7.7 years average duration of aspirin prescription, and 80mg as the median dose of aspirin. Cancer incidences were found in 26,929 (13.2%) aspirin users and 70,755 (17.3%) non-users. Compared with patients who had not been prescribed aspirin, aspirin usage led to significant reduction of cancers in liver (RR:0.49); stomach (RR:0.42); colorectum (RR:0.71); lung (RR:0.65); pancreas (RR:0.54); oesophagus (RR:0.59); and leukaemia (RR:0.67). There was no demonstrable reduction of kidney cancer, bladder cancer, prostate cancer and multiple myeloma in association with the usage of aspirin. Risk of breast cancer was shown to marginally increase (RR:1.14) with aspirin usage. This study demonstrated the long-term use of low-dose aspirin is associated with the reduction in risk of various cancers, but not for breast cancer. Further investigation is needed before promoting aspirin as a primary chemoprotective agent. This article is protected by copyright. All rights reserved.

KEYWORDS:

Aspirin; Cancer Incidence; Chinese; Hong Kong; Long-Term

PMID: 30575949 DOI: 10.1002/ijc.32083

***

[2] chp.gov.hk/en/healthtopics/...